Related Experiment Video

Updated: May 28, 2026

Autoradiography as a Simple and Powerful Method for Visualization and Characterization of Pharmacological Targets
10:16

Autoradiography as a Simple and Powerful Method for Visualization and Characterization of Pharmacological Targets

Published on: March 12, 2019

Characterization of a novel and selective CB1 antagonist as a radioligand for receptor occupancy studies

Yifan Yang1, Keith J Miller, Yeheng Zhu

  • 1Research & Development, Bristol-Myers Squibb Co., PO Box 4000, Princeton, New Jersey 08543, USA.

Bioorganic & Medicinal Chemistry Letters
|October 4, 2011
PubMed

Insights

Novel CB1 antagonists show promise for obesity treatment. A new radioligand aids in understanding how these drugs work in the body, linking lab results to real-world effectiveness.

Area of Science:

  • Pharmacology
  • Neuroscience
  • Endocrinology

Background:

  • Obesity is a major health concern linked to type II diabetes and cardiovascular disease.
  • Cannabinoid receptor 1 (CB1) antagonists show potential for appetite suppression and weight reduction.
  • Pre-clinical evaluation of CB1 antagonists requires correlating in vitro affinity with in vivo efficacy.

Purpose of the Study:

  • To synthesize and biologically evaluate a novel, highly selective radiolabeled CB1 antagonist.
  • To utilize the radioligand for ex vivo receptor occupancy studies.
  • To enhance the understanding of CB1 antagonist mechanisms.

Main Methods:

  • Synthesis of a novel radiolabeled CB1 antagonist.
  • Biological evaluation of the antagonist's selectivity and properties.
  • Conducting ex vivo receptor occupancy studies using the radioligand.

Main Results:

  • A novel, highly selective radiolabeled CB1 antagonist was successfully synthesized and evaluated.
  • The radioligand enabled effective ex vivo receptor occupancy studies.
  • Data suggests a correlation between in vitro and in vivo parameters for CB1 antagonists.

Conclusions:

  • The developed radioligand is a valuable tool for pre-clinical CB1 antagonist research.
  • Ex vivo receptor occupancy data aids in establishing structure-activity relationships.
  • This research supports the development of targeted obesity therapeutics.

More Related Videos

Receptor Autoradiography Protocol for the Localized Visualization of Angiotensin II Receptors12:03

Receptor Autoradiography Protocol for the Localized Visualization of Angiotensin II Receptors

Published on: June 7, 2016

Methods for the Discovery of Novel Compounds Modulating a Gamma-Aminobutyric Acid Receptor Type A Neurotransmission07:16

Methods for the Discovery of Novel Compounds Modulating a Gamma-Aminobutyric Acid Receptor Type A Neurotransmission

Published on: August 16, 2018

Related Concept Videos

Quantitative Aspects of Drug-Receptor Interaction01:30

Quantitative Aspects of Drug-Receptor Interaction

The receptor occupancy theory connects a drug's response to the number of occupied receptors. With higher drug concentrations, more receptors are occupied, leading to increased responses. The formation of drug-receptor complexes involves association and dissociation rates, which reach equilibrium when the forward and backward reactions are equal. The equilibrium association constant (Ka) and its inverse, the equilibrium dissociation constant (Kd), indicate drug affinity. Higher Ka and lower Kd...
The Two-State Receptor Model01:29

The Two-State Receptor Model

The two-state receptor model explains a drug's interaction with receptors, such as G protein-coupled receptors and ligand-gated ion channels, to induce or inhibit a biological response. When no natural ligands are present, a receptor exists in an equilibrium of inactive (Ri) and active (Ra) conformations. The inactive form does not produce a response, while the active form generates a basal effect known as constitutive activity.
The binding affinity of a drug determines its interaction with one...
Drug-Receptor Interactions01:29

Drug-Receptor Interactions

Drug-receptor interaction describes the binding of receptors by drugs, but not all drug-receptor interactions result in activation and tissue response. For instance, the binding of agonists activates the receptor to generate a cellular reaction, while antagonists bind to receptors without causing their activation.
Several parameters, such as the drug's affinity for its receptor and its efficacy, which is its ability to activate the receptor, determine the drug's effect on the tissue.
Drug-Receptor Interaction: Antagonist01:28

Drug-Receptor Interaction: Antagonist

An antagonist is a drug that binds strongly to a receptor without activating it. An antagonist prevents other molecules, such as neurotransmitters or hormones, from binding to the receptor and triggering a cellular response. Such interaction effectively hinders the normal physiological processes mediated by the receptor, resulting in various pharmacological effects depending on the specific receptor targeted.
Antagonists can be classified as competitive or noncompetitive based on their...
Drug-Receptor Interaction: Agonist01:25

Drug-Receptor Interaction: Agonist

Agonists are drugs that interact with specific receptors in the body to produce a biological response. When an agonist binds to a receptor, it activates or enhances the receptor's function, leading to physiological effects. The interaction between agonist drugs and receptors is crucial for their therapeutic action in various medical treatments.
Agonists can bind to receptors in different ways. Some agonists bind directly to the receptor's active site, mimicking the endogenous ligand's action.
Adrenergic Antagonists: Chemistry and Classification of ɑ-Receptor Blockers01:17

Adrenergic Antagonists: Chemistry and Classification of ɑ-Receptor Blockers

Adrenergic antagonists, or sympatholytics, inhibit adrenoceptor activation driven by catecholamines or agonists. Based on their adrenoceptor specificity, adrenergic blockers can be categorized into two primary groups: α-adrenergic blockers (α-blockers) and β-adrenergic blockers (β-blockers). α-blockers interact with α1 and α2 subtypes of α-adrenoceptors.
Nonselective α-blockers: Nonselective α-blockers contain haloalkylamine or imidazoline moieties. Phenoxybenzamine, with a haloalkylamine...